Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMUEL A KANTOR

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1316909864
CMS profile
332063
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$26,712.56

244 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMUEL A KANTOR

NPI 1316909864 · CMS profile ID 332063

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316909864?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMUEL A KANTOR, NPI 1316909864, CMS profile ID 332063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316909864?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SAMUEL A KANTOR, NPI 1316909864, CMS profile ID 332063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316909864?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SAMUEL A KANTOR, NPI 1316909864, CMS profile ID 332063, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1316909864?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

244 matching records · $26,712.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 244 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 244.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Relypsa, Inc. $3.8805/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683893979 CMS
Otsuka America Pharmaceutical, Inc. $115.0305/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687413107 CMS
Fresenius USA Marketing, Inc. $18.6405/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701836625 CMS
Fresenius USA Marketing, Inc. $0.8005/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701836633 CMS
Daiichi Sankyo Inc. $15.8705/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695323827 CMS
Amarin Pharma Inc. $5.9005/16/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699142207 CMS
Retrophin, Inc. $16.8105/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701823873 CMS
AKEBIA THERAPEUTICS INC $9.6305/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706559309 CMS
Alexion Pharmaceuticals, Inc. $106.4105/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695615561 CMS
Fresenius USA Marketing, Inc. $15.7905/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701841399 CMS
Fresenius USA Marketing, Inc. $1.0005/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701841403 CMS
Daiichi Sankyo Inc. $7.3105/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695323691 CMS
Fresenius USA Marketing, Inc. $1,000.0005/07/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701832969 CMS
Daiichi Sankyo Inc. $7.7705/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695405349 CMS
Amgen Inc. $15.9805/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662997743 CMS
Ultragenyx Pharmaceutical Inc. $110.7005/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703132841 CMS
Amarin Pharma Inc. $5.9005/02/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699135871 CMS
OPKO Pharmaceuticals, LLC $18.4905/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707773525 CMS
Fresenius USA Marketing, Inc. $81.7505/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701833535 CMS
Fresenius USA Marketing, Inc. $19.2605/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701833539 CMS
Fresenius USA Marketing, Inc. $2,000.0005/01/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701833543 CMS
Relypsa, Inc. $4.9705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683894811 CMS
Fresenius USA Marketing, Inc. $18.0104/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701840869 CMS
Fresenius USA Marketing, Inc. $0.7004/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701840877 CMS
Horizon Therapeutics plc $17.9404/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691409777 CMS
Novo Nordisk Inc $68.5204/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703523045 CMS
Otsuka America Pharmaceutical, Inc. $20.8904/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687413105 CMS
Relypsa, Inc. $5.7304/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683895329 CMS
Amicus Therapeutics, Inc. $29.5904/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699827207 CMS
FUJIFILM Wako Diagnostics U.S.A. Corporation $100.5304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701446859 CMS
Janssen Pharmaceuticals, Inc $116.3104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658810515 CMS
Amgen Inc. $23.1804/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662997725 CMS
Daiichi Sankyo Inc. $0.2804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695360999 CMS
Daiichi Sankyo Inc. $6.5604/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695361003 CMS
Otsuka America Pharmaceutical, Inc. $121.8304/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687413129 CMS
Fresenius USA Marketing, Inc. $17.2504/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701840227 CMS
Otsuka America Pharmaceutical, Inc. $2.7404/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687413127 CMS
AstraZeneca Pharmaceuticals LP $96.1704/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685340113 CMS
AstraZeneca Pharmaceuticals LP $21.5304/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685193769 CMS
Otsuka America Pharmaceutical, Inc. $10.0704/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687413103 CMS
Otsuka America Pharmaceutical, Inc. $19.2404/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687413101 CMS
Genentech USA, Inc. $100.0004/01/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681275835 CMS
Novo Nordisk Inc $16.2804/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669522677 CMS
AstraZeneca Pharmaceuticals LP $11.8503/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685925607 CMS
Biogen, Inc. $113.1603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660659147 CMS
GlaxoSmithKline, LLC. $13.7703/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671102349 CMS
Alexion Pharmaceuticals, Inc. $17.7603/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695615291 CMS
Daiichi Sankyo Inc. $3.1403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695308851 CMS
Daiichi Sankyo Inc. $4.3703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695308853 CMS
Alexion Pharmaceuticals, Inc. $32.0403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695615287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,712.56 244
PY2020 $7,958.89 135
PY2021 $52,522.73 243
PY2022 $81,147.05 304
PY2023 $68,933.37 244
PY2024 $40,231.23 247
PY2025 $41,989.01 235

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $47,819.04 14
PY2022 Principal investigator $213,274.87 80
PY2021 Principal investigator $134,550.26 37
PY2020 Principal investigator $141,788.75 29
PY2019 Principal investigator $158,224.22 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,520.20 12/31/2023 Non-covered Recipient Entity
NEVADA KIDNEY DISEASE AND HYPERTENSION CENTERS
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia No dispute reported 06/30/2026 991124695
Principal investigator 1 AKEBIA THERAPEUTICS INC $300.00 07/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919933
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,600.00 06/20/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919983
Principal investigator 1 AKEBIA THERAPEUTICS INC $300.00 06/20/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999920005
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,225.00 03/01/2023 Non-covered Recipient Entity
FRESENIUS MEDICAL CARE NORTH AMERICA
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1017235017
Principal investigator 1 AKEBIA THERAPEUTICS INC $157.00 02/27/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919899
Principal investigator 1 AKEBIA THERAPEUTICS INC $117.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919811
Principal investigator 1 AKEBIA THERAPEUTICS INC $157.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919833
Principal investigator 1 AKEBIA THERAPEUTICS INC $203.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919853
Principal investigator 1 AKEBIA THERAPEUTICS INC $349.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919877
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,200.00 01/19/2023 Non-covered Recipient Entity
Nevada Kidney Disease and Hypertension Centers, PLLC (SMO)
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999919957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,982.56 01/19/2023 Non-covered Recipient Entity
NEVADA KIDNEY DISEASE AND HYPERTENSION CENTERS
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia No dispute reported 06/30/2026 991128007
Principal investigator 1 Novartis Pharmaceuticals Corporation $248.28 01/10/2023 Non-covered Recipient Entity
FRENOVA SMO
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1017187777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,460.00 01/01/2023 Non-covered Recipient Entity
Nevada Kidney Disease And Hypertension Center-Fire Mesa
BI 685509 Dose finding PoCC in Non Diabetic CKD No dispute reported 06/30/2026 1022142485